Diffuse Large B-Cell Lymphoma: Clinical Trials

31 trials for Diffuse Large B-Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

31 terminated. 31 Phase 2, 6 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 231Terminated 31
Phase 16Terminated 6
Phase 31Terminated 1

Follow Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Diffuse Large B-Cell Lymphoma trials Research Report on Diffuse Large B-Cell Lymphoma

Trials (filtered) newest first · largest first

All 31 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
maplirpacept (PF-07901801), Glofitamab, Obinutuzumab - Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2TerminatedPfizer402023-08-302026-05-06
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Maplirpacept, Tafasitamab, Lenalidomide - Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2TerminatedPfizer62023-08-042025-09-05
Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma
Epcoritamab, Lenalidomide - Diffuse Large B-Cell Lymphoma
Phase 2TerminatedGenmab1112023-03-062026-10-23
Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Polatuzumab vedotin (PV), Rituximab, Hyaluronidase - Diffuse Large B-cell Lymphoma
Phase 2TerminatedUNC Lineberger Comprehensive Cancer Center52023-02-172026-04-16
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
Loncastuximab Tesirine, Rituximab - Diffuse Large B-cell Lymphoma
Phase 2TerminatedADC Therapeutics S.A.412022-06-212025-01-30
A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL
ATG-010, Lenalidomide, Rituximab - Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
Phase 1 / Phase 2TerminatedAntengene Corporation542022-04-072025-06-09
A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]
THOR-707, Pembrolizumab - Classic Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma
Phase 2TerminatedSanofi142021-12-072025-12-24
Reduction of MTX Levels After Glucarpidase Treatment in DLBCL Patients at Risk of CNS
Glucarpidase 1000 UNT [Voraxaze] - Diffuse Large B-Cell Lymphoma, Drug Toxicity
Phase 2TerminatedFundacion CRIS de Investigación para Vencer el Cáncer32021-07-192024-05-13
ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma
ME-401, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2TerminatedDeepa Jagadeesh132021-04-282025-02-07
Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma
Copanlisib - Diffuse Large B-cell Lymphoma
Phase 2TerminatedFondazione Italiana Linfomi - ETS372020-08-182025-08-08
First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
GEN3009, Epcoritamab - Diffuse Large B-cell Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2TerminatedGenmab462020-03-132024-10-24
Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
Loncastuximab Tesirine, Ibrutinib - Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma
Phase 1 / Phase 2TerminatedADC Therapeutics S.A.1362018-12-012024-02-06
TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
TAK-659 - Diffuse Large B-cell Lymphoma
Phase 2TerminatedCalithera Biosciences, Inc492017-10-102023-02-08
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 2TerminatedFred Hutchinson Cancer Center1502017-09-112026-05-14
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Thymoglobulin, Bortezomib, Tacrolimus - Acute Leukemia, Chronic Lymphocytic Leukemia
Phase 2TerminatedEmory University52016-09-012018-04-30
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Ublituximab, Umbralisib, Bendamustine - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Phase 2 / Phase 3TerminatedTG Therapeutics, Inc.7102016-05-252022-07-21
DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma
Metformin - Diffuse Large B-Cell Lymphoma
Phase 2TerminatedRush University Medical Center22016-02-012017-11-17
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
Bendamustine Hydrochloride, Obinutuzumab, Dexamethasone - Diffuse Large B-Cell Lymphoma
Phase 2TerminatedUniversity of Chicago22015-11-012018-06-06
Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)
Metformin, Rituximab, Cyclophosphamide - Diffuse Large B-Cell Lymphoma
Phase 2TerminatedRush University Medical Center52015-07-012022-09-28
A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL
DPX-Survivac, Cyclophosphamide - Diffuse Large B-Cell Lymphoma
Phase 2TerminatedImmunoVaccine Technologies, Inc. (IMV Inc.)42015-01-012021-06-22

Showing 20 of 31. Sign in to see all of them.

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (31)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (7)  ·  Lymphoma, Mantle-Cell (7)  ·  Lymphoma (6)  ·  Recurrence (6)  ·  Lymphoma, Follicular (4)  ·  Lymphoma, B-Cell, Marginal Zone (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)  ·  Myelodysplastic Syndromes (2)  ·  Waldenstrom Macroglobulinemia (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Dendritic Cell Sarcoma, Interdigitating (1)  ·  Drug-Related Side Effects and Adverse Reactions (1)  ·  Graft vs Host Disease (1)

Broader conditions

Hemic and Lymphatic Diseases (31)  ·  Immune System Diseases (31)  ·  Immunoproliferative Disorders (31)  ·  Lymphatic Diseases (31)  ·  Lymphoma, B-Cell (31)  ·  Lymphoproliferative Disorders (31)  ·  Neoplasms (31)  ·  Neoplasms by Histologic Type (31)  ·  Lymphoma, Non-Hodgkin (28)  ·  Lymphoma (25)  ·  Disease Attributes (12)  ·  Pathologic Processes (12)  ·  Pathological Conditions, Signs and Symptoms (12)  ·  Chronic Disease (7)  ·  Leukemia, B-Cell (7)

Interventions

Rituximab (8)  ·  Cyclophosphamide (5)  ·  Lenalidomide (5)  ·  Dexamethasone (3)  ·  6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (2)  ·  Bendamustine Hydrochloride (2)  ·  Doxorubicin (2)  ·  Metformin (2)  ·  Prednisone (2)  ·  Vincristine (2)  ·  ibritumomab tiuxetan (2)  ·  loncastuximab tesirine (2)  ·  obinutuzumab (2)  ·  Antilymphocyte Serum (1)  ·  Bortezomib (1)

Sponsors

ADC Therapeutics S.A. (2)  ·  Genmab (2)  ·  Gilead Sciences (2)  ·  Pfizer (2)  ·  Rush University Medical Center (2)  ·  Anne Beaven, MD (1)  ·  Antengene Corporation (1)  ·  Calithera Biosciences, Inc (1)  ·  Celgene Corporation (1)  ·  Chulalongkorn University (1)  ·  Deepa Jagadeesh (1)  ·  Emory University (1)  ·  Fondazione Italiana Linfomi - ETS (1)  ·  Fred Hutchinson Cancer Center (1)  ·  Fudan University (1)

Countries

United States (20)  ·  Italy (8)  ·  Spain (8)  ·  Canada (4)  ·  France (4)  ·  United Kingdom (4)  ·  Belgium (3)  ·  Japan (3)  ·  South Korea (3)  ·  Australia (2)  ·  China (2)  ·  Israel (2)  ·  Poland (2)  ·  Argentina (1)  ·  Austria (1)

Top investigators

Reem Karmali, MD (2)  ·  Adolfo De la Fuente, PD (1)  ·  Andrew Spencer, MD (1)  ·  Anne W. Beaven, MD (1)  ·  Barbara Botto, MD (1)  ·  Christopher Dittus, DO, MPH (1)  ·  Deepa Jagadeesh, MD, MPH (1)  ·  Ken Cohen (1)  ·  Masumi Ueda Oshima (1)  ·  Owen A O'Connor, MD, PhD (1)

Results publications

PMID 25696919, PMID 26968534, PMID 33683917, PMID 41043099, PMID 42285113

NIH funding

2009 (1), 2016 (1), 2018 (1), 2019 (1), 2023 (1), P01CA078902 (1), P30CA014599 (1), P30CA015704 (1)